文献速递银屑病与炎症性皮肤病

银屑病多生物制剂治疗失败的相关因素:CorEvitas登记队列分析

Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry.
PubMed 文献 · J Am Acad Dermatol · 2023-07-24

该前瞻性队列分析纳入CorEvitas银屑病登记中2015-2020年启动首个生物制剂并随访≥24个月的患者,比较多生物制剂失败(MBF)与良好临床应答(GR)的特征。结果显示女性、较短银屑病病程、较早启动年份、既往非生物系统治疗、高脂血症史和Medicaid保险与MBF显著相关。MBF中最常见的一线至二线序列为TNF-α抑制剂转为IL-17抑制剂。

要点

  • 约6%的银屑病患者符合多生物制剂失败标准。
  • 女性、较短病程、较早启动年份、既往非生物系统治疗与MBF显著相关。
  • 高脂血症史和Medicaid保险与MBF相关但置信区间较宽。

核心结论

  • 约6%的银屑病患者符合MBF标准,研究识别出与MBF相关的特征,可能有助于区分需要更频繁随访的患者。

研究设计与样本

  • 前瞻性队列分析,评估多中心CorEvitas银屑病登记中2015-2020年启动首个生物制剂并随访≥24个月的患者,采用多变量逻辑回归分析。

主要发现

  • 女性、较短银屑病病程、较早的生物制剂启动年份、既往非生物系统治疗使用、高脂血症史和Medicaid保险与MBF显著相关,其中后2个变量置信区间较宽。
  • MBF中最常见的第一至第二生物制剂序列为TNF-α抑制剂转为IL-17抑制剂。

局限性

  • 未评估就诊间期的生物制剂依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis patients with poor therapeutic response to multiple biologic agents are not well-characterized. OBJECTIVE: To describe the characteristics associated with development of multiple biologic failure (MBF) versus good clinical response (GR) to the first biologic. METHODS: This prospective cohort analysis evaluated patients in the multicenter CorEvitas Psoriasis Registry who initiated their first biologic between 2015 and 2020 and were followed for ≥24 months. Multivariable logistic regression identified sociodemographic, clinical, and patient-reported outcomes that differed between MBF (discontinued ≥2 biologics of different classes, each used for ≥90 days, due to inadequate efficacy) and GR (continued use of first biologic for ≥2 years) patients. RESULTS: One thousand thirty-nine patients were analyzed (490 GR [47.2%], 65 MBF [6.3%]). Female sex, shorter psoriasis duration, earlier year of biologic initiation, prior nonbiologic systemic therapy use, history of hyperlipidemia, and Medicaid insurance were significantly associated with MBF, though the latter 2 variables exhibited wider confidence intervals, indicating a lower level of support. The first-to-second biologic sequence most observed with MBF was Tumor necrosis factor-α inhibitor to IL-17 inhibitor use. LIMITATIONS: Biologic adherence between visits was not evaluated. CONCLUSION: Approximately 6% of psoriasis patients met MBF criteria. The results identify characteristics associated with MBF that may distinguish patients warranting more frequent follow-up.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Jin JQ, Cronin A, Roberts-Toler C, et al. Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry. J Am Acad Dermatol. 2023. PMID: 37495173. doi:10.1016/j.jaad.2023.06.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。